HomeCompareIDRSF vs QYLD

IDRSF vs QYLD: Dividend Comparison 2026

IDRSF yields 48.90% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDRSF wins by $346.8K in total portfolio value
10 years
IDRSF
IDRSF
● Live price
48.90%
Share price
$4.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$372.2K
Annual income
$74,100.38
Full IDRSF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — IDRSF vs QYLD

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDRSFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDRSF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDRSF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF
Annual income on $10K today (after 15% tax)
$4,156.48/yr
After 10yr DRIP, annual income (after tax)
$62,985.32/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, IDRSF beats the other by $58,174.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + QYLD for your $10,000?

IDRSF: 50%QYLD: 50%
100% QYLD50/50100% IDRSF
Portfolio after 10yr
$198.8K
Annual income
$39,879.85/yr
Blended yield
20.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IDRSF right now

IDRSF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-10.1
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys
0
QYLD buys
0
No recent congressional trades found for IDRSF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDRSFQYLD
Forward yield48.90%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$372.2K$25.4K
Annual income after 10y$74,100.38$5,659.31
Total dividends collected$295.4K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IDRSF vs QYLD ($10,000, DRIP)

YearIDRSF PortfolioIDRSF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$15,590$4,889.98$10,352$1,192.36+$5.2KIDRSF
2$23,806$7,124.73$10,830$1,347.57+$13.0KIDRSF
3$35,640$10,167.77$11,460$1,539.07+$24.2KIDRSF
4$52,361$14,226.41$12,275$1,777.84+$40.1KIDRSF
5$75,560$19,533.63$13,323$2,078.95+$62.2KIDRSF
6$107,194$26,344.00$14,667$2,463.34+$92.5KIDRSF
7$149,625$34,927.92$16,396$2,960.57+$133.2KIDRSF
8$205,663$45,564.28$18,631$3,612.97+$187.0KIDRSF
9$278,591$58,531.92$21,548$4,482.15+$257.0KIDRSF
10$372,193$74,100.38$25,398$5,659.31+$346.8KIDRSF

IDRSF vs QYLD: Complete Analysis 2026

IDRSFStock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this IDRSF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHDIDRSF vs JEPIIDRSF vs OIDRSF vs KOIDRSF vs MAINIDRSF vs XYLDIDRSF vs JEPQIDRSF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.